(VIANEWS) – Simpson Manufacturing Company (SSD), Targa Resources (TRGP), Vertex Pharmaceuticals (VRTX) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Simpson Manufacturing Company (SSD)

41.3% sales growth and 21.72% return on equity

Simpson Manufacturing Co., Inc., through its subsidiaries, designs, engineers, manufactures, and sells wood and concrete building construction products.

Simpson Manufacturing Company’s sales growth this year is expected to be 20.6% and 17.8% for next year.

Year-on-year quarterly revenue growth grew by 8.9%, now sitting on 1.45B for the twelve trailing months.

Volume

Today’s last reported volume for Simpson Manufacturing Company is 42738 which is 68.8% below its average volume of 136987.

Simpson Manufacturing Company’s sales growth for the next quarter is 41.3%. The company’s growth estimates for the current quarter and the next is 39.7% and 1.7%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 21.72%.

Volatility

Simpson Manufacturing Company’s last day, last week, and last month’s current intraday variation average was 2.95%, 1.46%, and 1.47%, respectively.

Simpson Manufacturing Company’s highest amplitude of average volatility was 2.38% (day), 2.12% (last week), and 2.32% (last month), respectively.

Simpson Manufacturing Company’s Stock Yearly Top and Bottom Value

Simpson Manufacturing Company’s stock is valued at $117.94 at 00:22 EST, under its 52-week high of $123.54 and way higher than its 52-week low of $88.61.

Simpson Manufacturing Company’s Moving Average

Simpson Manufacturing Company’s worth is higher than its 50-day moving average of $114.11 and higher than its 200-day moving average of $110.21.

2. Targa Resources (TRGP)

28.4% sales growth and 12.9% return on equity

Targa Resources Corp., together with its subsidiary, Targa Resources Partners LP, owns, operates, acquires, and develops a portfolio of midstream energy assets in North America.

Targa Resources’s sales growth this year is expected to be 79.5% and 5.5% for next year.

Year-on-year quarterly revenue growth grew by 110.9%, now sitting on 14.08B for the twelve trailing months.

Volume

Today’s last reported volume for Targa Resources is 1374180 which is 7.65% above its average volume of 1276420.

Targa Resources’s sales growth for the next quarter is 28.4%. The company’s growth estimates for the ongoing quarter and the next is a negative 0% and 35.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.9%.

Volatility

Targa Resources’s last day, last week, and last month’s current intraday variation average was 1.53%, 2.60%, and 1.72%, respectively.

Targa Resources’s highest amplitude of average volatility was 6.05% (day), 4.47% (last week), and 3.07% (last month), respectively.

Targa Resources’s Stock Yearly Top and Bottom Value

Targa Resources’s stock is valued at $50.85 at 00:22 EST, way below its 52-week high of $58.18 and way above its 52-week low of $24.27.

Targa Resources’s Moving Average

Targa Resources’s value is under its 50-day moving average of $53.66 and way higher than its 200-day moving average of $42.79.

3. Vertex Pharmaceuticals (VRTX)

17.4% sales growth and 24.64% return on equity

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis.

Vertex Pharmaceuticals’s sales growth this year is expected to be 17.5% and 10.5% for next year.

Year-on-year quarterly revenue growth grew by 29%, now sitting on 7.13B for the twelve trailing months.

Volume

Today’s last reported volume for Vertex Pharmaceuticals is 712052 which is 60.82% below its average volume of 1817650.

Vertex Pharmaceuticals’s sales growth is a negative 0% for the current quarter and 17.4% for the next. The company’s growth estimates for the ongoing quarter and the next is 15.9% and 24.7%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.64%.

Volatility

Vertex Pharmaceuticals’s last day, last week, and last month’s current intraday variation average was 1.48%, 0.43%, and 0.42%, respectively.

Vertex Pharmaceuticals’s highest amplitude of average volatility was 1.41% (day), 1.64% (last week), and 1.65% (last month), respectively.

Vertex Pharmaceuticals’s Stock Yearly Top and Bottom Value

Vertex Pharmaceuticals’s stock is valued at $211.13 at 00:22 EST, way below its 52-week high of $242.99 and way above its 52-week low of $176.36.

Vertex Pharmaceuticals’s Moving Average

Vertex Pharmaceuticals’s value is way above its 50-day moving average of $184.35 and higher than its 200-day moving average of $200.51.

4. Organogenesis Holdings (ORGO)

15.8% sales growth and 17.8% return on equity

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States.

Organogenesis Holdings ‘s sales growth this year is expected to be 36.7% and 10.7% for next year.

Year-on-year quarterly revenue growth grew by 43.1%, now sitting on 338.3M for the twelve trailing months.

Volume

Today’s last reported volume for Organogenesis Holdings is 363294 which is 67.24% below its average volume of 1109280.

Organogenesis Holdings ‘s sales growth for the next quarter is 15.8%. The company’s growth estimates for the ongoing quarter and the next is a negative 68.4% and negative -40%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.8%.

Volatility

Organogenesis Holdings ‘s last day, last week, and last month’s current intraday variation average was 2.17%, 3.27%, and 2.65%, respectively.

Organogenesis Holdings ‘s highest amplitude of average volatility was 6.67% (day), 6.21% (last week), and 5.65% (last month), respectively.

Organogenesis Holdings ‘s Stock Yearly Top and Bottom Value

Organogenesis Holdings ‘s stock is valued at $9.66 at 00:22 EST, way below its 52-week high of $24.34 and way above its 52-week low of $4.80.

Organogenesis Holdings ‘s Moving Average

Organogenesis Holdings ‘s value is way under its 50-day moving average of $10.95 and way under its 200-day moving average of $15.59.

5. NeoGenomics (NEO)

12.1% sales growth and 5.42% return on equity

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia.

NeoGenomics’s sales growth this year is expected to be 9% and 16% for next year.

Year-on-year quarterly revenue growth declined by 3.3%, now sitting on 484.59M for the twelve trailing months.

Volume

Today’s last reported volume for NeoGenomics is 1058800 which is 6.36% above its average volume of 995407.

NeoGenomics’s sales growth for the next quarter is 12.1%. The company’s growth estimates for the present quarter and the next is a negative 200% and negative -275%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.42%.

Volatility

NeoGenomics’s last day, last week, and last month’s current intraday variation average was 6.07%, 3.76%, and 3.74%, respectively.

NeoGenomics’s highest amplitude of average volatility was 8.82% (day), 7.15% (last week), and 6.11% (last month), respectively.

NeoGenomics’s Stock Yearly Top and Bottom Value

NeoGenomics’s stock is valued at $30.49 at 00:22 EST, way under its 52-week high of $61.57 and higher than its 52-week low of $30.15.

NeoGenomics’s Moving Average

NeoGenomics’s value is way below its 50-day moving average of $42.27 and way below its 200-day moving average of $44.96.

6. Canadian National Railway Company (CNI)

6.1% sales growth and 23.01% return on equity

Canadian National Railway Company, together with its subsidiaries, engages in the rail and related transportation business.

Canadian National Railway Company’s sales growth this year is anticipated to be 6.4% and 7.8% for next year.

Year-on-year quarterly revenue growth grew by 5.3%, now sitting on 14.38B for the twelve trailing months.

Volume

Today’s last reported volume for Canadian National Railway Company is 1135540 which is 35.43% below its average volume of 1758810.

Canadian National Railway Company’s sales growth is a negative 0% for the ongoing quarter and 6.1% for the next. The company’s growth estimates for the present quarter and the next is 15% and 9.6%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.01%.

Volatility

Canadian National Railway Company’s last day, last week, and last month’s current intraday variation average was 1.21%, 2.27%, and 1.79%, respectively.

Canadian National Railway Company’s highest amplitude of average volatility was 1.66% (day), 1.44% (last week), and 2.04% (last month), respectively.

Canadian National Railway Company’s Stock Yearly Top and Bottom Value

Canadian National Railway Company’s stock is valued at $126.57 at 00:22 EST, under its 52-week high of $136.22 and way higher than its 52-week low of $100.66.

Canadian National Railway Company’s Moving Average

Canadian National Railway Company’s value is under its 50-day moving average of $127.60 and higher than its 200-day moving average of $115.25.

LEAVE A REPLY

Please enter your comment!
Please enter your name here